Oppenheimer lowered the firm’s price target on UnitedHealth (UNH) to $400 from $600 and keeps an Outperform rating on the shares. The firm is following up after UnitedHealth’s announcement/call with changes to its model and updated comments. As a reminder, the company announced that CEO Andrew Witty will be replaced by long-time, successful CEO Stephen Hemsley. UnitedHealth also suspended full year 2025 guidance due to increases in care activity across its Medicare book and as the new CEO gets his arms around the business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $450 from $575 at KeyBanc
- UnitedHealth price target lowered to $356 from $510 at Baird
- UnitedHealth price target lowered to $374 from $563 at Morgan Stanley
- UnitedHealth price target lowered to $362 from $521 at Deutsche Bank
- UnitedHealth price target lowered to $351 from $677 at Wells Fargo